Production Linked Incentive Scheme (PLI) for Pharmaceuticals and Medical Devices

Strengthening Domestic Manufacturing and Achieving Self-Reliance

Introduction

The Government of India launched the Production Linked Incentive (PLI) Scheme as a cornerstone initiative to boost domestic manufacturing and enhance Indias global competitiveness. While initially focused on electronics manufacturing, the scheme was quickly expanded to critical sectors, including Pharmaceuticals and Medical Devices. This strategic move aims to reduce Indias dependence on imports, specifically for Active Pharmaceutical Ingredients (APIs) and high-end medical equipment, while positioning the country as a global manufacturing hub.

By offering financial incentives to eligible companies for incremental production, the scheme intends to attract large investments in the healthcare supply chain. This not only ensures the availability of essential medicines and devices for the domestic population but also opens up immense export opportunities in the international market.

Objectives of the PLI Scheme

The primary goal of the PLI schemes for Pharma and MedTech is to create a robust ecosystem for manufacturing in India. The specific objectives include:

• Enhancing Domestic Manufacturing: To significantly increase the production volume of critical starting materials, drug intermediates, and medical devices within the country.
• Reducing Import Dependence: To cut down the reliance on imports, particularly from China, for Key Starting Materials (KSMs), APIs, and major medical devices.
• Improving Quality Standards: To encourage domestic manufacturers to upgrade their facilities to meet global Good Manufacturing Practices (GMP) and international quality standards.
• Generating Employment: To create skilled and semi-skilled job opportunities across the pharmaceutical and medical device manufacturing sectors.
• Attracting Foreign Investment: To draw global leaders to set up base in India, bringing with them advanced technology and research capabilities.

The Importance of Self-Reliance

Prior to the introduction of the PLI scheme, India was often referred to as the "Pharmacy of the World" due to its massive generic drug exports. However, this distinction masked a significant vulnerability: the country relied heavily on imports (over 60-70%) for the raw materials required to make these medicines. The COVID-19 pandemic highlighted the risks associated with this supply chain fragility. The PLI scheme serves as a direct response to this challenge, ensuring national health security by securing the supply chain from raw materials to finished formulations.

PLI Scheme for Pharmaceuticals

The Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, notified the PLI scheme for Pharmaceuticals in July 2020. With a financial outlay of 15,000 crore, the scheme focuses on three specific categories:

Incentive Structure

The scheme offers financial incentives to eligible applicants for a period of six years. The incentive is calculated on the basis of incremental sales. The rates vary from 5% to 10% of incremental sales, depending on the category and the tier of the product. Priority is given to products where India has a high dependency on imports or those that have high potential for exports.

Eligibility and Selection

Eligibility is determined by the applicant's manufacturing capabilities and their commitment to minimum investment thresholds. For the formulation segment, the scheme encourages global players to set up greenfield (new) manufacturing units in India or expand existing brownfield facilities. This ensures that the domestic market is not only supplied by local companies but also benefits from the efficiency and scale of multinational corporations.

PLI Scheme for Medical Devices

Parallel to the pharma initiative, the PLI scheme for Medical Devices was launched in 2020 with an outlay of 3,420 crore. The medical devices sector in India is highly import-dependent, with nearly 80% of requirements being met through imports. This scheme targets the promotion of domestic manufacturing of critical medical devices.

Targeted Segments

The scheme identifies specific target segments that have a large market size and high import value. These include:

• Implants and Disposables: Consumables like syringes, needles, catheters, and surgical drapes.
• Imaging Devices: MRI machines, CT scans, and X-ray systems.
• Dialysis Equipment: Machines and consumables required for renal care.
• Respiratory Devices: Oxygen concentrators, ventilators, and sleep apnea devices.
• Cardiology and Rhythm Management: Pacemakers, stents, and heart valves.

Mechanism of the Incentive

Similar to the pharma scheme, the incentive for medical devices is tied to incremental sales over a base year. The rate is generally around 5% of incremental sales for a period of five years. To prevent crowding out of existing small manufacturers who may not meet the high investment thresholds, the scheme includes a specific component to incentivize the manufacturing of certain medical devices by Micro, Small, and Medium Enterprises (MSMEs). This ensures inclusivity within the broader industrial growth.

Strategic Impact and Benefits

The implementation of the PLI schemes marks a paradigm shift in Indias industrial policy. It moves away from protectionist measures toward an incentive-based model that rewards performance.

Economic Growth and Exports

By scaling up production capabilities, India aims to capture a larger share of the global medical devices market, which is currently dominated by China, the US, and Europe. Increased exports will improve the countrys Balance of Payments situation and contribute significantly to GDP growth.

Technological Advancement

The requirement to meet global quality standards acts as a catalyst for technological upgradation. Companies are compelled to adopt modern manufacturing processes, automation, and quality control systems. This infusion of technology will have spillover effects on other associated industries, raising the overall technological baseline of Indian engineering.

Healthcare Accessibility and Affordability

One of the most critical outcomes of this scheme is the potential reduction in the cost of healthcare. As raw materials and devices are manufactured locally, logistics costs decrease, and import duties become irrelevant. This downward pressure on costs is expected to make medicines and medical devices more affordable for the common citizen, thereby improving public health outcomes.

Supply Chain Resilience

Diversifying the supply chain is a matter of national security. The PLI scheme ensures that in times of global crisis, India is not left scrambling for essential medicines like antibiotics or life-saving equipment like ventilators. A self-reliant supply chain acts as a buffer against geopolitical shocks and trade disruptions.

Implementation and Progress

The schemes are being monitored closely by the Nodal Agencies (DPIP and DBT for various segments). Since the launch, several global giants have expressed interest or have already committed to setting up manufacturing bases in India. Domestic companies have also begun expanding their capacities to qualify for the incentives.

The government has structured the application process to be transparent and competitive. Companies are selected based on their manufacturing capacity, revenue potential, and commitment to investing in India. This merit-based selection ensures that only serious and capable players benefit from the financial outlay.

Conclusion

The Production Linked Incentive Scheme for Pharmaceuticals and Medical Devices is a transformative initiative. It addresses the structural weaknesses in India's healthcare manufacturing sector while leveraging its strengths in chemistry and engineering. By incentivizing investment in high-value manufacturing, the scheme promises to reduce import dependency, create millions of jobs, and provide affordable healthcare solutions to millions of Indians.

Over the next few years, as the incentives take effect, we can expect a significant shift in the landscape of Indian healthcare manufacturing. The successful execution of this scheme is vital for realizing the vision of an Atmanirbhar Bharat (Self-Reliant India), ensuring that the nation is equipped to handle its internal health demands while emerging as a dominant player in the global healthcare supply chain.